» Articles » PMID: 34387841

Pentalinonsterol, a Phytosterol from Pentalinon Andrieuxii, is Immunomodulatory Through Phospholipase A in Macrophages Toward Its Antileishmanial Action

Overview
Date 2021 Aug 13
PMID 34387841
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Our earlier in vitro and in vivo studies have revealed that the phytosterol, pentalinonsterol (cholest-4,20,24-trien-3-one) (PEN), isolated from the roots of Pentalinon andrieuxii, possesss immunomodulatory properties in macrophages and dendritic cells. Leishmaniasis, caused by the infection of Leishmania spp. (a protozoan parasite), is emerging as the second-leading cause of mortality among the tropical diseases and there is an unmet need for a pharmacological intervention of leishmaniasis. Given the beneficial immunomodulatory actions and lipophilic properties of PEN, the objective of this study was to elucidate the mechanism(s) of action of the immunomodulatory action(s) of PEN in macrophages through the modulation of phospholipase A (PLA) activity that might be crucial in the antileishmanial action of PEN. Therefore, in this study, we investigated whether PEN would modulate the activity of PLA in RAW 264.7 macrophages and mouse bone marrow-derived primary macrophages (BMDMs) in vitro and further determined how the upstream PLA activation would regulate the downstream cytokine release in the macrophages. Our current results demonstrated that (i) PEN induced PLA activation (arachidonic acid release) in a dose- and time-dependent manner that was regulated upstream by the mitogen-activated protein kinases (MAPKs); (ii) the PEN-induced activation of PLA was attenuated by the cPLA-specific pharmacological inhibitors; and (iii) the cPLA-specific pharmacological inhibitors attenuated the release of inflammatory cytokines from the macrophages. For the first time, our current study demonstrated that PEN exhibited its immunomodulatory actions through the activation of cPLA in the macrophages, which potentially could be used in the development of a pharmacological intervention against leishmaniasis.

Citing Articles

Immunomodulatory Effect of Phytoactive Compounds on Human Health: A Narrative Review Integrated with Bioinformatics Approach.

Choudhary S, Khan S, Rustagi S, Rajpal V, Khan N, Kumar N Curr Top Med Chem. 2024; 24(12):1075-1100.

PMID: 38551050 DOI: 10.2174/0115680266274272240321065039.


The Impacts of Cholesterol, Oxysterols, and Cholesterol Lowering Dietary Compounds on the Immune System.

Yanagisawa R, He C, Asai A, Hellwig M, Henle T, Toda M Int J Mol Sci. 2022; 23(20).

PMID: 36293093 PMC: 9602982. DOI: 10.3390/ijms232012236.

References
1.
Mashayekhi-Ghoyonlo V, Kiafar B, Rohani M, Esmaeili H, Erfanian-Taghvaee M . Correlation between Socioeconomic Status and Clinical Course in Patients with Cutaneous Leishmaniasis. J Cutan Med Surg. 2015; 19(1):40-4. DOI: 10.2310/7750.2014.13216. View

2.
Varikuti S, Oghumu S, Saljoughian N, Pioso M, Sedmak B, Khamesipour A . Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana. Acta Trop. 2017; 173:102-108. PMC: 5731240. DOI: 10.1016/j.actatropica.2017.06.004. View

3.
Veiga J, Rosa T, Kimachi T, Wolff E, Sampaio R, Gagliardi A . [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds]. Rev Inst Med Trop Sao Paulo. 1985; 27(6):298-302. DOI: 10.1590/s0036-46651985000600002. View

4.
Sundar S, More D, Singh M, Singh V, Sharma S, Makharia A . Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000; 31(4):1104-7. DOI: 10.1086/318121. View

5.
Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E . Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis. 1999; 180(2):564-7. DOI: 10.1086/314896. View